Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response

Abstract

Background Few studies have investigated the long-term outcomes of secukinumab in real-life psoriasis treatment where diverse patient profiles require a personalized approach. Objectives To determine long-term performance of secukinumab in moderate-to-severe plaque psoriasis, and identify potential clinical factors predictive of sustained optimal response under real-world conditions. Methods In this 78-week, single-centre, retrospective study, effectiveness, safety and drug survival of secukinumab were evaluated. Effectiveness data are reported as observed. Co-primary endpoints were absolute Psoriasis Area and Severity Index (PASI) ≤3 at week 4, 16, 52, 78, and clinical predictors of PASI ≤3 and PASI100 responses at week 52 and 78. Results A total of 85 patients (75.3% male; mean age 48.6 years) were included. Absolute PASI ≤3 was achieved in 73% and 83% of patients at week 52 and 78, respectively. PASI 75/90/100 responses at week 52 (71.6%, 50.8%, and 40.3%, respectively) were sustained at week 78 (73.6%, 64.2%, and 45.3%, respectively). Median absolute PASI remained low at week 52/78 (0.9/0.6, respectively), while mean absolute PGA also sustained low (0-1) values after 16-78 weeks. Investigator's Global Assessment 0/1 response rate was maintained by week 52/78 (72/83%, respectively). The drug survival rate of secukinumab at week 78 was 79.1%. Treatment was discontinued in 17.9% of patients after an average of 41.7 weeks, mainly due to loss of effectiveness (10.4%). A total of 27% experienced adverse events, without critical safety concerns. Based on multivariate analysis, advanced body mass index (BMI) and presence of ≥3 comorbidities decreased the chance of achieving PASI ≤3 at week 78 [OR (95% CI) 0.78 (0.64-0.97); P = 0.024, and OR (95% CI) 0.045 (0.002-0.83); P = 0.037, respectively]. Conclusions Secukinumab showed consistently high effectiveness in this real-life cohort, with an acceptable safety profile. Over time, persistence of PASI ≤3 response appears to be lower in patients with high BMI or multiple comorbidities.

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

“…It has been reported that patients with BMI ≥30 had a lower response to secukinumab. [ 11 , 12 ] However, this was not seen in our study. In some studies, age and comorbidities were believed to affect the bioavailability and biotherapeutics of biological medications.…”

Secukinumab: A complete approach to psoriatic patients—Real‐world evidence study

“…These results are similar or numerically slightly higher compared to the ones previously reported in real-world cohorts. 2,5,7 The percentages of patients with a PASI score of ≤1, ≤2, ≤3 and ≤5 were higher at all studied time points when compared to other studies, 8 albeit there seems to be no major differences between bio-naïve and bio-experienced patients, similar to other studies. 9 One possible reason for these similar results between groups is that the majority of bio-experienced patients (70%) was previously exposed to only one biologic, being therefore less difficult to treat than patients with two or more previous biological therapies.…”

“…Psoriasis is a chronic and debilitating immune-mediated inflammatory disease, associated with an increased risk for comorbidities and a substantial psychologic and socioeconomic impact that can last a lifetime, 1,2 for which secukinumab has demonstrated high efficacy and a very favorable safety profile in several real-world studies. [3][4][5][6] This retrospective single-center cohort study collected data from 66 patients treated with secukinumab up to 40 weeks in a real-world setting, and evaluated secukinumab drug survival, effectiveness and safety profile.…”

“…

Psoriasis is a chronic and debilitating immune-mediated inflammatory disease, associated with an increased risk for comorbidities and a substantial psychologic and socioeconomic impact that can last a lifetime, 1,2 for which secukinumab has demonstrated high efficacy and a very favorable safety profile in several real-world studies. [3][4][5][6] This retrospective single-center cohort study collected data from 66 patients treated with secukinumab up to 40 weeks in a real-world setting, and evaluated secukinumab drug survival, effectiveness and safety profile.The study population consisted of consecutive moderate to severe plaque psoriasis (PsO) patients, with or without psoriatic arthritis (PsA), attending one Psoriasis Clinic in Lisbon, Portugal, who were treated with secukinumab. This study was conducted according to the tenets of the Declaration of Helsinki.Effectiveness outcomes include psoriasis area and severity index (PASI).

…”

Clinical and Quality of Life Outcomes Among Ixekizumab -Treated Psoriasis Patients in a Real-World Setting: Results from a Single US Dermatology Referral Practice

“…(9, 10) While rapid response and long-term effectiveness were indicated to be of high importance among patients with moderate to severe disease as well as physicians making treatment decisions, (2,11) there is evidence that current biologic treatments may lose effectiveness over time. (12), (13,14) The newer biologic therapies are those that inhibit the IL-17 or IL-23 pathways. Ixekizumab (Taltz®, IXE), an IL-17 antagonist, was approved in the US on March 22, 2016 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.…”